Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
AiCuris
AiCuris
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part I
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
Resolving capping issues in tablet manufacturing
Natoli explores the various causes of capping and the methods to prevent it
Effective ways to optimise heat exchangers
Heat exchangers are used within a wide range of process industries as a way to transfer heat between two fluid streams across a medium in an energy conservative way
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Upcoming event
Lounges
23-25 April 2024 | Conference | Messe Karlsruhe, Germany
See all
Related Content
Ingredients
AiCuris initiates clinical development of AIC499, a novel resistance-breaking antibiotic
Programme supported by the Innovative Medicines Initiative
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Can new discoveries prevent an antibiotic Armageddon?
Governments are waking up to the catastrophe of drug resistance and healthcare without antibiotics. But is extra funding the answer or could the pharma industry be doing more?
Research & Development
COMBACTE-MAGNET project aims to stimulate antibiotic development in Europe
Seven-year project brings together 33 European academic partners and five pharmaceutical companies
Regulatory
Antiviral agent – letermovir
Cytomegalovirus (CMV) can cause severe difficulties in patients with compromised immune systems, such as people with HIV infection or those who are undergoing organ or bone marrow transplantation
Subscribe now